Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

News

News
Proposed Bevacizumab Biosimilar BAT1706 Found Equivalent to Reference Bevacizumab for Advanced Nonsquamous Non-Small Cell Lung Cancer
11/22/2023
According to a phase 3 trial, the proposed bevacizumab biosimilar BAT1706 was found equivalent to reference biosimilar for the treatment of patients with advanced nonsquamous non-small cell lung cancer.
According to a phase 3 trial, the proposed bevacizumab biosimilar BAT1706 was found equivalent to reference biosimilar for the treatment of patients with advanced nonsquamous non-small cell lung cancer.
According to a phase 3 trial,...
11/22/2023
Oncology
News
Pertuzumab Biosimilar QL1209 Demonstrated Equivalent Efficacy, Safety to Reference Pertuzumab Among Patients With HER2-Positive Breast Cancer
11/06/2023
According to a phase 3 study, QL1209, a pertuzumab biosimilar, was found to have comparable efficacy, safety, and immunogenicity to the reference product among patients with HER2-positive breast cancer.
According to a phase 3 study, QL1209, a pertuzumab biosimilar, was found to have comparable efficacy, safety, and immunogenicity to the reference product among patients with HER2-positive breast cancer.
According to a phase 3 study,...
11/06/2023
Oncology
News
Bevacizumab Biosimilar Efficacy, Safety for Patients With Metastatic Colorectal Cancer
10/10/2023
According to real-world data, the bevacizumab biosimilar, bevacizumab-awwb, was found to be as effective and safe as the bevacizumab reference product for patients with metastatic colorectal cancer.
According to real-world data, the bevacizumab biosimilar, bevacizumab-awwb, was found to be as effective and safe as the bevacizumab reference product for patients with metastatic colorectal cancer.
According to real-world data,...
10/10/2023
Oncology

Advertisement

News
Docetaxel-PM Plus Trastuzumab Biosimilar Showed Antitumor Activity Among Patients With HER2-Positive Salivary Duct Carcinoma
10/10/2023
According to a phase 2 trial, combination docetaxel-PM and trastuzumab-pkrb demonstrated antitumor activity among patients with HER2-positive salivary duct carcinoma.
According to a phase 2 trial, combination docetaxel-PM and trastuzumab-pkrb demonstrated antitumor activity among patients with HER2-positive salivary duct carcinoma.
According to a phase 2 trial,...
10/10/2023
Oncology
News
Patients Report Satisfaction With Biosimilar Treatment, But Demonstrate Lack of Overall Knowledge
09/11/2023
According to a systematic review, patients are satisfied with biosimilar treatments but have limited knowledge about biosimilars, a lack of which can affect their perceptions of the clinical effects and regulation process.
According to a systematic review, patients are satisfied with biosimilar treatments but have limited knowledge about biosimilars, a lack of which can affect their perceptions of the clinical effects and regulation process.
According to a systematic...
09/11/2023
Oncology
News
Biosimilar Rituximab Plus CHOP Effective, Well-Tolerated Among Patients With Previously Untreated CD20-Positive DLBCL
09/07/2023
The rituximab biosimilar, SDZ-RTX, combined with a CHOP regimen was effective and well-tolerated as a frontline treatment for patients with diffuse large B-cell lymphoma (DLBCL), according to a real-world study.
The rituximab biosimilar, SDZ-RTX, combined with a CHOP regimen was effective and well-tolerated as a frontline treatment for patients with diffuse large B-cell lymphoma (DLBCL), according to a real-world study.
The rituximab biosimilar,...
09/07/2023
Oncology

Advertisement

News
Serplulimab Plus Bevacizumab Biosimilar Showed Efficacy, Safety Among Patients With Hepatocellular Carcinoma
09/05/2023
According to a results from a phase 2 study, serplulimab plus HLX04, a bevacizumab biosimilar, showed promising antitumor activity and manageable safety among patients with previously treated advanced hepatocellular carcinoma.
According to a results from a phase 2 study, serplulimab plus HLX04, a bevacizumab biosimilar, showed promising antitumor activity and manageable safety among patients with previously treated advanced hepatocellular carcinoma.
According to a results from a...
09/05/2023
Oncology
News
Trastuzumab Biosimilar Plus Paclitaxel Shows Promise for Patients With HER2-Positive Recurrent or Metastatic Urothelial Carcinoma
08/04/2023
In a phase 2 trial, the trastuzumab biosimilar, trastuzumab-pkrb, plus paclitaxel demonstrated promising efficacy and manageable toxicity among patients with HER2-positive urothelial carcinoma.
In a phase 2 trial, the trastuzumab biosimilar, trastuzumab-pkrb, plus paclitaxel demonstrated promising efficacy and manageable toxicity among patients with HER2-positive urothelial carcinoma.
In a phase 2 trial, the...
08/04/2023
Oncology
News
Bevacizumab Biosimilar Demonstrated Similar Efficacy, Safety as Reference Product Among Patients With Metastatic Colorectal Cancer
07/31/2023
The bevacizumab biosimilar, bevacizumab-awwb, was effective and well-tolerated in the first-line setting among patients with metastatic colorectal cancer.
The bevacizumab biosimilar, bevacizumab-awwb, was effective and well-tolerated in the first-line setting among patients with metastatic colorectal cancer.
The bevacizumab biosimilar,...
07/31/2023
Oncology

Advertisement

News
Bevacizumab Biosimilar Candidate TAB008 Comparable to Reference Bevacizumab for Patients With Locally Advanced, Metastatic EGFR Wild-Type Non-Squamous NSCLC
07/10/2023
In a phase 3 study, biosimilar candidate TAB008 was found to be similar to reference bevacizumab in terms of efficacy and safety for patients with locally advanced, metastatic EGFR wild-type non-squamous non-small cell lung cancer.
In a phase 3 study, biosimilar candidate TAB008 was found to be similar to reference bevacizumab in terms of efficacy and safety for patients with locally advanced, metastatic EGFR wild-type non-squamous non-small cell lung cancer.
In a phase 3 study, biosimilar...
07/10/2023
Oncology

Advertisement

Advertisement

Advertisement

Recent News

News
Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer
11/14/2024
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective...
11/14/2024
Oncology
News
Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer
11/14/2024
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the...
11/14/2024
Oncology
News
Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma
11/13/2024
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2...
11/13/2024
Oncology
News
Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
11/12/2024
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial,...
11/12/2024
Oncology
News
Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer
11/12/2024
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from...
11/12/2024
Oncology
News
Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer
11/11/2024
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a...
11/11/2024
Oncology
FDA Approval
FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia
11/08/2024
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA...
11/08/2024
Oncology
News
Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer
11/07/2024
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus...
11/07/2024
Oncology
News
Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
11/06/2024
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a...
11/06/2024
Oncology
News
Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma
11/05/2024
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study...
11/05/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use